Register for tracking leptomeningeal disease in Germany

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter register aims to create a comprehensive database on the incidence and progression of leptomeningeal disease in Germany. It collects data on therapeutic measures and complications experienced by patients in real-world settings. Patients eligible for the register will provide informed consent, and their clinical data will be documented without any interventions or health risks involved. The register will utilize diagnostic findings and routine clinical practice letters from participating medical centers to gather information.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with leptomeningeal disease
* Written consent of the patient or legal guardian.
* Capacity to give consent or legal guardianship
* Age ≥ 18 years

Exclusion Criteria:

* Lack of informed consent from the patient
* Lack of capacity to consent on the part of the person concerned or lack of legal guardianship
* Age \< 18 years

Where it's running

• Universitätsklinikum Bonn Klinik und Poliklinik für Neurologie
  Bonn, Germany Recruiting
• Universitätsmedizin Mannheim Universitätsklinikum Mannheim GmbH Klinik für Neurologie
  Mannheim, Germany Recruiting
• Klinikum rechts der Isar | Technische Universität München; Klinik für Radioonkologie und Strahlentherapie
  München, Germany Recruiting
• Diakonie Klinikum GmbH • Jung-Stilling-KrankenhausAbteilung Neurochirurgie
  Siegen, Germany Recruiting
• University Hospital Tübingen, Neurooncology
  Tübingen, Germany Recruiting
• Universitätsklinikum Ulm; Klinik für Innere Medizin III
  Ulm, Germany Recruiting

Study contacts

• Study coordinator: Ghazaleh Tabatabai, Prof
• Email: Tabatabai.Office@med.uni-tuebingen.de
• Phone: +497071-29

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dendritic Cell Vaccine with HER2-targeted Therapy or Nivolumab for Breast Cancer with Leptomeningeal Metastasis

  This trial tests a dendritic cell vaccine added to trastuzumab for Her2-positive disease or to nivolumab for Her2-negative disease to see if it can be given safely to people with breast cancer that has spread to the leptomeninges.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07694986

• Optimizing gadopiclenol MRI to detect early leptomeningeal disease

  This study tests whether using gadopiclenol during brain MRI can improve early detection of leptomeningeal disease in adults with solid cancers.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07415018

• B7-H3 CAR T cells for recurrent brain tumors in kids and young adults

  This early-phase trial tests a personalized CAR T-cell therapy called B7-H3 CAR T for children and young adults with recurrent or progressive brain tumors.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07390539

• Assessment of patients with leptomeningeal metastasis

  This study is trying to create a standard way to check how patients with leptomeningeal metastases are doing, so doctors can better understand and manage their condition.

  Recruiting at 3 sites University of Zurich · Houston, Texas and 2 other locations · NCT06417710

• Treatment for breast cancer patients with leptomeningeal disease

  This study is testing a new treatment combining tucatinib, capecitabine, and intrathecal trastuzumab to see if it can help people with HER2-positive metastatic breast cancer and leptomeningeal disease live longer.

  Recruiting at 10 sites Phase 2 Unicancer · Bordeaux and 10 other locations · NCT05800275

• Using PD1 antibody for treating leptomeningeal disease in metastatic solid tumors

  This study is testing if giving a PD1 antibody directly into the spine can help people with leptomeningeal disease from metastatic solid tumors feel better and stay safe.

  Recruiting at 8 sites Phase 1 University Hospital Tuebingen · Bonn and 8 other locations · NCT05112549

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.